Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oxybutynin + darifenacin
- Development stage
- Preclinical
- Lead developer
- Allergan
- Modality
- Small Molecules
- Administration
- Oral, Transdermal
01
Overview
A combination of two anticholinergic medications used to treat overactive bladder (OAB). Oxybutynin is a non-selective muscarinic receptor antagonist while darifenacin is a selective M3 muscarinic receptor antagonist. This combination may provide enhanced efficacy for patients with refractory OAB, though with potential increased risk of anticholinergic side effects.
02
Targets
CHRM2 (M2)M1 (Muscarinic acetylcholine receptor M1)CHRM3 (M3)
Beyond the preview
Go deeper on oxybutynin + darifenacin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oxybutynin + darifenacin.